Action AFMD AFFIMED N.V.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Affimed N.V.

Actions

AFMD

NL0015001ZQ0

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 01/05/2024 		Varia. 5j. Varia. 1 janv.
5,33 USD -0,37% Graphique intraday de Affimed N.V. +9,22% -14,72%
01/04 AFFIMED N.V. : Wells Fargo Securities toujours positif ZM
01/04 AFFIMED N.V. : HC Wainwright à l'achat ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
Affimed Reports 2023 Financial Results and Operational Progress
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
Affimed N : Form 6-K
Affimed Announces 1-for-10 Reverse Stock Split
AFFIMED ANNOUNCES LEADERSHIP CHANGE AND ORGANIZATIONAL RESTRUCTURING
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer
Affimed Announces Leadership Change and Organizational Restructuring
Affimed N.V. Announces CEO Changes
Affimed N.V. Announces Management Changes
Sector Update: Health Care Stocks Mixed Late Afternoon
Sector Update: Health Care Stocks Gain in Afternoon Trading
Affimed to Sell AbCheck to Ampersand Biomedicines for $6 Million in Cash, Stock; Shares Fall
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
Ampersand Biomedicines Inc. entered into a definitive agreement to acquire AbCheck s.r.o. from Affimed N.V. for $6.4 million.
Affimed N.V.(NasdaqCM:AFMD) dropped from NASDAQ Biotechnology Index
AFFIMED ANNOUNCES UPDATED PHASE DATA FROM ACIMTAMIG IN COMBINATION WITH ALLOGENEIC NK IN HODGKIN LYMPHOMA PATIENTS WHO FAILED PRIOR CHEMOTHERAPY AND ARE DOUBLE-REFRACTORY TO BRENTUXIMAB VEDOTIN AND CHECKPOINT INHIBITORS
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AFMD
  4. Actualités Affimed N.V.
  5. Autres langues